FDA Approvals in Oncology: July-September 2025
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
Category: Policy
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
Richard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed...
A workshop hosted by AACR and FDA explored novel clinical trial oncology endpoints and considerations for their validation and...
In the second quarter of 2025, the FDA issued 13 new oncology approvals, including options for rare cancers, head...
A congressional forum hosted by Senators Tammy Baldwin and Peter Welch examined how NIH funding cuts could impact cancer...
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
Natalie Snider-Hoy, a PhD candidate at Wayne State University, attended AACR Early-career Hill Day 2025 to advocate for sustained...
In the final three months of 2024, the FDA issued 15 approvals in oncology, including several therapies that are...
Ten-year-old Michael Methner told his story about his experience being diagnosed with optic nerve glioma at the Rally for...
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...